| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 2.9 | 1.8 |
| Profit before tax | -20.2 | -29.8 |
| Net income | -20.2 | -29.8 |
| EPS (diluted, $ a share) | $-0.16 | $-0.69 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +63.1% |
|---|
10-Q filed with the SEC, NASDAQ: XFOR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
X4 Pharmaceuticals, Inc: key numbers
- Share price
- $2.83Close, Nov 16
- Market cap
- $289M
- Shares outstanding
- 102.11MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from X4 Pharmaceuticals, Inc
All →X4 Pharmaceuticals Investor Presentation
X4 Pharmaceuticals is hosting a Virtual Investor Day on October 29, 2026, to provide updates on its strategic business plans and clinical pipeline. The presentation focuses on the commercialization of mavorixafor for primary chronic neutropenia and the progress of the ongoing 4WARD Phase 3 clinical study.
X4 Pharmaceuticals Executive Chairman Adam R. Craig Buys $11.9K of Stock
Adam R. Craig, Executive Chairman, bought 4,600 shares of X4 Pharmaceuticals, Inc at $2.58 a share, worth $11.9K in total on Oct 16, 2026. Shares held after the trade: 333,251 (+1.4%).
- Value
- $11.9K
- Shares
- 4,600
- Price
- $2.58
- Role
- Executive Chairman
- Holding change
- +1.4%
- Trade date
- Oct 16, 2026
X4 Pharmaceuticals $150M Debt Financing with K2 HealthVentures LLC
X4 Pharmaceuticals entered into a $150 million senior secured term loan facility with K2 HealthVentures, consisting of an immediate $80 million tranche and an additional $70 million available upon request and lender approval. The proceeds were used to repay an existing $75 million loan from Hercules and will support the potential commercial launch of mavorixafor. The new facility features a 48-month maturity and an interest-only period through at least October 2029.
- Value
- $150M
- Counterparty
- K2 HealthVentures LLC
- Term
- 4 years
X4 Pharmaceuticals CFO David Kirske Sells $33.7K of Stock
David Kirske, CFO, sold 11,767 shares of X4 Pharmaceuticals, Inc at $2.86 a share, worth $33.7K in total on Oct 1, 2026. Shares held after the trade: 155,983 (-7.0%).
- Value
- $33.7K
- Shares
- 11,767
- Price
- $2.86
- Role
- CFO
- Holding change
- -7.0%
- Trade date
- Oct 1, 2026